Press Releases IP Group Plc

Equities

IPO

GB00B128J450

Market Closed - London S.E. Other stock markets 11:35:08 2024-04-30 EDT			5-day change	1st Jan Change
47.95 ^GBX	-2.24%		-0.72%	-17.47%

04-29	EARNINGS: One Media IP Group annual profit down but asset value steady	AN
04-23	Alphawave confident in long term growth potential as revenue rises	AN

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IP : Genomics plc and GSK establish precision medicine collaboration to assess polygenic risk scores in clinical trial design	10:16am	PU
IP : Notice of the 2024 Annual General Meeting	04-24	PU
IP : First Light Fusion - First Light Founder moves into new science-focused role with Acting CEO appointed	04-22	PU
IP : Kynos Therapeutics announces positive top line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement	04-22	PU
IP : First Light Fusion solves major engineering challenge in the design of an Inertial Confinement Fusion pilot power plant	04-03	PU
IP : Tissue Regenix Group plc - Final results for the year ended 31 December 2023	03-19	PU
Mission Therapeutics raises GBP25.2 million to progress clinical candidates in the area of mitophagy	03-15	AQ
IP : Mission Therapeutics raises £25.2 million to progress clinical candidates in the area of mitophagy	03-14	PU
IP : Moa Techology - Moa to develop next-gen bioherbicides in new 10-year commercial partnership with Croda	03-13	PU
IP : Oxford Nanopore Technologies and SeqOne partner to support interpretation of nanopore sequencing in clinical use	03-12	PU
IP : Quantum Dice And HSBC Collaborate On The Use Of QRNGs To Enhance Financial Monte Carlo Simulations	03-05	PU
IP : Oxford Nanopore Technologies plc - Directorate Change	03-01	PU
IP : Oxford Nanopore Technologies plc - Appoints Two Non-Executive Directors	12-19	PU
IP : Ultraleap and Prophesee enter into a strategic partnership to provide industry-first hand tracking on event sensors for AR devices	12-19	PU
IP : Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury	12-14	PU
IP : AccelerComm Expands LDPC Accelerator IP Licenses for 5G Cloud RAN High-Capacity Solutions	12-13	PU
IP : STORM Therapeutics’ First-in-Class tRNA methyltransferase inhibitor of METTL1 to be Presented at the 65th Annual ASH Conference	12-08	PU
IP : Oxford Nanopore Technologies - Nanopore Community Meeting Technology Update	12-07	PU
IP : Crescendo Biologics - Announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC	12-06	PU
IP : Oxford Quantum Circuits - OQC & Classiq Partner to Advance Seamless Quantum Computing and Data Center Convergence	12-05	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases IP Group Plc

Equities

IPO

GB00B128J450

Press Releases

Filters